CY1111840T1 - Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson - Google Patents

Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson

Info

Publication number
CY1111840T1
CY1111840T1 CY20111100887T CY111100887T CY1111840T1 CY 1111840 T1 CY1111840 T1 CY 1111840T1 CY 20111100887 T CY20111100887 T CY 20111100887T CY 111100887 T CY111100887 T CY 111100887T CY 1111840 T1 CY1111840 T1 CY 1111840T1
Authority
CY
Cyprus
Prior art keywords
methoxy
carboxamide
pyridin
dichloro
pyridine
Prior art date
Application number
CY20111100887T
Other languages
Greek (el)
English (en)
Inventor
Philippe Delay-Goyet
Claire Delgorge
Christine Menet
Gilles Poughon
Christine Ravinet-Trillou
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of CY1111840T1 publication Critical patent/CY1111840T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CY20111100887T 2007-04-19 2011-09-15 Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson CY1111840T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
EP08787963A EP2146714B1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
CY1111840T1 true CY1111840T1 (el) 2015-10-07

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100887T CY1111840T1 (el) 2007-04-19 2011-09-15 Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson

Country Status (33)

Country Link
US (1) US20100130554A1 (https=)
EP (1) EP2146714B1 (https=)
JP (1) JP5386478B2 (https=)
KR (2) KR20150004885A (https=)
CN (1) CN101663035B (https=)
AR (1) AR066108A1 (https=)
AT (1) ATE513548T1 (https=)
AU (1) AU2008257322B2 (https=)
BR (1) BRPI0810444A2 (https=)
CA (1) CA2684174C (https=)
CL (1) CL2008001136A1 (https=)
CY (1) CY1111840T1 (https=)
DK (1) DK2146714T3 (https=)
EA (1) EA019194B1 (https=)
ES (1) ES2367408T3 (https=)
FR (1) FR2915100B1 (https=)
HR (1) HRP20110666T1 (https=)
IL (1) IL201448A (https=)
JO (1) JO2678B1 (https=)
MA (1) MA31367B1 (https=)
ME (1) ME00935B (https=)
MX (1) MX2009011284A (https=)
MY (1) MY148092A (https=)
NZ (1) NZ580482A (https=)
PA (1) PA8776801A1 (https=)
PL (1) PL2146714T3 (https=)
PT (1) PT2146714E (https=)
RS (1) RS51869B (https=)
SI (1) SI2146714T1 (https=)
TW (1) TWI439269B (https=)
UY (1) UY31035A1 (https=)
WO (1) WO2008145841A1 (https=)
ZA (1) ZA200907251B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955808A (zh) * 2012-11-28 2015-09-30 赛诺菲 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的晶型的制备方法以及晶型
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
US20250120957A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
CA2160928C (en) * 1993-07-28 2005-07-05 Garry Fenton Compounds as pde iv and tnf inhibitors
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
JP2005506286A (ja) * 2001-03-02 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリック−ａｍｐ関連疾患の治療を目的としたメラノコルチン受容体アゴニストおよびホスホジエステラーゼ阻害剤の併用投与
EP1519922A1 (en) * 2002-07-02 2005-04-06 Merck Frosst Canada & Co. Di-aryl-substituted ethane pyridone pde4 inhibitors
US6911464B2 (en) * 2003-03-12 2005-06-28 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
MA31367B1 (fr) 2010-05-03
PL2146714T3 (pl) 2011-10-31
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
FR2915100B1 (fr) 2009-06-05
KR20090130059A (ko) 2009-12-17
ATE513548T1 (de) 2011-07-15
CN101663035B (zh) 2012-06-20
PA8776801A1 (es) 2008-11-19
ME00935B (me) 2012-06-20
TW200911247A (en) 2009-03-16
CA2684174A1 (fr) 2008-12-04
ES2367408T3 (es) 2011-11-03
IL201448A (en) 2014-08-31
CA2684174C (fr) 2014-02-25
SI2146714T1 (sl) 2011-10-28
UY31035A1 (es) 2008-11-28
AR066108A1 (es) 2009-07-22
NZ580482A (en) 2011-10-28
KR101503942B1 (ko) 2015-03-18
EA019194B1 (ru) 2014-01-30
CL2008001136A1 (es) 2009-01-16
ZA200907251B (en) 2011-04-28
HK1141725A1 (en) 2010-11-19
JO2678B1 (en) 2013-03-03
WO2008145841A1 (fr) 2008-12-04
AU2008257322B2 (en) 2013-06-13
HRP20110666T1 (hr) 2011-10-31
EA200970970A1 (ru) 2010-02-26
KR20150004885A (ko) 2015-01-13
JP5386478B2 (ja) 2014-01-15
EP2146714A1 (fr) 2010-01-27
FR2915100A1 (fr) 2008-10-24
EP2146714B1 (fr) 2011-06-22
JP2010524906A (ja) 2010-07-22
TWI439269B (zh) 2014-06-01
IL201448A0 (en) 2010-05-31
RS51869B (sr) 2012-02-29
MX2009011284A (es) 2009-11-02
MY148092A (en) 2013-02-28
CN101663035A (zh) 2010-03-03
US20100130554A1 (en) 2010-05-27
PT2146714E (pt) 2011-09-02
AU2008257322A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
LTC2937350I2 (lt) 1'-pakeistieji karba-nukleozidų analogai, skirti antivirusiniam gydymui
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
CY2016040I2 (el) Επιλογες θεραπειας για τη νοσο του fabry
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
NO20084531L (no) Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser
CY1108324T1 (el) Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης
BRPI0914802A2 (pt) Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2008000461A1 (es) Uso de aclidinio en el tratamiento o prevencion de una enfermedad o un estado respiratorio en un paciente por inhalacion, sin producir en dicho paciente efectos antimuscarinicos sistemicos.
BRPI0810774A2 (pt) composição de cuidado oral ou cuidado corporal.
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
CR20110552A (es) Tratamiento de transtornos resistentes a la insulina
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
BRPI0807804A2 (pt) " arilciclopentenos substituídos como agentes terapêuticos ".
CY1111840T1 (el) Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson
DK2175877T3 (da) Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme
CY1111779T1 (el) Χρηση του 4-κυκλοπροπυλομεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλο)-5-(μεθοξυ)πυριδινο-2-καρβοξαμιδιου για τη θεραπευτικη αντιμετωπιση των τραυματισμων του νωτιαιου μυελου
UA114486C2 (uk) Застосування 4-амінопіридину у лікуванні пов'язаної з інсультом сенсорно-рухової недостатності
CY1111534T1 (el) Χρηση αλατων τιοτροπιου στην αντιμετωπιση μετριου επιμονου ασθματος
DE502004011919D1 (de) -trien-3-yl sulfamate
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК